Wyeth

American Home Products Corporation

Other

Robert E McDevitt

Folake O Adebayo

Michael Sotirios Malamas

Scott Christian Mayer

Paul Jeffrey Dollings

Alexander Greenfield

John Anthony Butera

Craig E Caufield

Michael David Collini

Iwan Suwandi Gunawan

Alan Howard Katz

Eric Gould Gundersen

Joseph R Lennox

Eric Steven Manas

Lisa Marie Havran

Russell Graceffa

James C Keith, Jr

Heather Anne Harris

Leo M Albert

Albert Jean Robichaud

Ronald Charles Bernotas

Yanfang Li

Hassan Mahmoud Elokdah

Gavin David Heffernan

Kevin G Liu

Geraldine Ruth McFarlane

Richard Dale Coghlan

C Richard Lyttle

Russell F Graceffa

P Sivaramakrishnan Ramamoorthy

Cristina Grosanu

Jennifer Rebecca Lo

Cecil Richard Lyttle

Folake O Adebi

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.

Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors

This invention provides estrogen receptor modulators of formula I, having the structure whereinR, R, R, R, R, and R, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Substituted benzoxazoles as estrogenic agents

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R, R, R, R, R, R, R, W, Y, and Z are defined herein; or a pharmaceutically acceptable salt thereof.

Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation

This invention provides estrogen receptor modulators of formula I, having the structure wherein R, R, R, R, R, and R, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure 

This invention provides estrogen receptor modulators of formula I, having the structure wherein

Compounds of Formula I or a pharmaceutically acceptable salt thereof are provided: where Rthrough Rare defined herein. The compounds of Formula I are 5HT2agonists or partial agonists, and are useful for treating a variety of disorders.

1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents

This invention provides compounds of Formula I having the structureor a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia

This invention provides estrogen receptor modulators of formula I, having the structureR, R, and Rare as defined in the specification, or a pharmaceutically acceptable salt thereof.

Substituted indenones as estrogenic agents

Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia

Growing community of inventors

Somerset, NJ, United States of America

Robert E McDevitt